MCTL THERAPY
FOR BREAST CANCER

Breast cancer treatment has advanced enormously over the past two decades — but several patient groups still face limited options when standard therapies fail. Triple-negative breast cancer (TNBC) lacks targeted therapy options; metastatic HER2-positive disease eventually progresses through HER2-targeted therapies; and heavily pre-treated metastatic disease often runs out of effective standard options. MCTL therapy is being studied specifically to address these gaps.

“For patients running out of standard breast cancer options, multi-antigen T cell therapy represents a new way of attacking the disease — engaging the immune system against multiple targets simultaneously.”

• Triple-Negative Breast Cancer (TNBC) Lacks Targeted Therapy

  TNBC lacks ER, PR, and HER2 — eliminating the main targeted therapy categories. Treatment relies primarily on chemotherapy ± immunotherapy. After first- and second-line failure, options become very limited. MCTL's multi-antigen approach can target TNBC-associated antigens that are not addressed by standard treatments.

• HER2+ Metastatic Disease Eventually Progresses

  Multiple HER2-targeted therapies (trastuzumab, pertuzumab, T-DM1, trastuzumab deruxtecan, tucatinib) have transformed HER2+ outcomes. But all eventually fail. MCTL targeting HER2 alongside other breast antigens may extend the therapeutic options after HER2-targeted failure.

Breast cancer cells express a wide range of antigens that, in principle, the immune system could recognise — but immune evasion mechanisms typically prevent this from happening naturally. MCTL is designed to overcome this by educating expanded T cells against multiple breast antigens simultaneously.

• HER2 (ERBB2)

  The classical HER2 antigen targeted by trastuzumab and other HER2-directed drugs. MCTL approaches HER2 from a different angle — through T cell recognition rather than antibody binding. This means HER2+ patients who have failed antibody-based HER2 therapies may still respond to MCTL targeting HER2.

• MUC1 (Mucin-1)

  MUC1 is overexpressed on most breast cancers, including TNBC. The tumour-associated form (aberrantly glycosylated MUC1) is distinct from the normal-tissue form, providing tumour-selective targeting.

• Survivin

  Survivin is overexpressed in most cancers including breast and plays a role in tumour cell survival. T cells educated to recognise survivin target a fundamental cancer biology rather than a tissue-specific marker.

• NY-ESO-1

  A cancer/testis antigen expressed in approximately 20–40% of breast cancers (particularly TNBC) and in normal testis only. The restricted normal expression makes it a relatively safe immunotherapy target — T cells attacking NY-ESO-1 do not damage other healthy tissues.

• Additional Targets

  WT1, MAGE-A family antigens, hTERT, and other breast cancer–associated antigens are included in some MCTL protocols depending on the patient's tumour expression profile. Targeting multiple antigens simultaneously means losing one (antigen escape) does not eliminate immune recognition.

How MCTL is being studied across different breast cancer subtypes — and where the rationale is strongest.

Patients considering MCTL for breast cancer deserve a clear picture of where the evidence stands. The therapy shows promise, but it is not yet at the level of established standard treatments.

• What the Evidence Shows

  Phase I/II trials at Chinese cancer centres have demonstrated feasibility, safety, and signals of clinical activity in heavily pre-treated breast cancer patients. Manufacturing success rates are high. Toxicity has been generally manageable. Disease control rates in some trials approach 40–60% in patients who had progressed through multiple prior lines.

• What the Evidence Does Not Show

  No phase III randomised trials have established MCTL as superior to standard treatments. Long-term durable responses are uncommon in published series. The optimal patient selection, dosing, and combination strategies are still being defined. Comparing single-arm trial results to historical controls has substantial limitations.

• Reasonable Conclusion

  For breast cancer patients who have exhausted established therapies and who have realistic understanding of the evidence stage, MCTL through a Chinese clinical trial is a reasonable option to consider. For patients who still have meaningful established treatment options, standard treatments should generally be pursued first.

The end-to-end pathway from initial evaluation through cell infusion and follow-up.

1. 1

   Step 1: Eligibility Evaluation

   Review of pathology (subtype, biomarkers), prior treatment history, current disease status (imaging), performance status, organ function, and tumour antigen expression profile. Inclusion in a specific MCTL protocol depends on the trial criteria and the patient's case.

2. 2

   Step 2: Apheresis (T Cell Collection)

   Outpatient procedure: 3–6 hours of blood collection through an apheresis machine to harvest T cells. Patient returns home the same day. Cells are cryopreserved and shipped to the manufacturing facility.

3. 3

   Step 3: MCTL Manufacturing (2–3 Weeks)

   Laboratory expansion and education of T cells against multiple breast cancer–associated antigens. Quality control verifies target specificity and viability before release.

4. 4

   Step 4: Lymphodepletion Chemotherapy (Pre-Infusion)

   Mild conditioning chemotherapy over 3–5 days to create immunological space for the infused cells. Typically less intensive than CAR-T lymphodepletion regimens.

5. 5

   Step 5: MCTL Cell Infusion

   Single intravenous infusion of expanded MCTL cells. Procedure takes 30–60 minutes; patient remains in hospital for monitoring.

6. 6

   Step 6: Hospital Monitoring (1–2 Weeks)

   Close monitoring for cytokine release syndrome, neurological effects, and early signs of response. Most patients are discharged 7–14 days after infusion.

7. 7

   Step 7: Response Assessment and Follow-Up

   First response assessment at 4–6 weeks with imaging and tumour markers. Subsequent assessments every 6–8 weeks. Possible additional doses depending on protocol and response.

MCTL for breast cancer is most commonly accessed through Chinese clinical trials or specialist centre programmes. Eligibility is more selective than standard treatments.

• Strong Candidates

  Patients with histologically confirmed advanced breast cancer who have progressed through standard therapies (typically 2+ prior lines), have ECOG performance status 0–1, adequate organ function (cardiac, renal, hepatic), and disease that expresses target antigens. Sufficient bone marrow reserve to tolerate lymphodepletion is essential.

• Patients Less Likely to Qualify

  Active uncontrolled infections, severe cardiac disease, recent CNS disease without stable control, very poor performance status (ECOG 3–4), uncontrolled brain metastases, or end-stage organ failure typically exclude patients. Patients with significant remaining standard treatment options are usually directed to those first.

Explore the MCTL therapy knowledge base.

Frequently Asked Questions

Common questions about MCTL therapy for breast cancer.